Failure of antimonial drugs, the mainstay therapy for leishmaniasis has become an escalating problem in the treatment of Indian leishmaniasis. Using 14 clinical isolates from both visceral (VL) and post-kala-azar dermal leismaniasis (PKDL) patients, we have examined the role of ATP-binding cassette transporter (ABC transporter) gene, multidrug resistant protein A (MRPA) and two building blocks of the major thiol, trypanothione namely, ornithine decarboxylase gene (ODC) (a rate limiting enzyme in the polyamine biosynthesis) and γglutamylcysteine synthetase (γ-GCS) (a rate limiting enzyme in glutathione biosynthesis) in antimony resistance. Amplification of these three genes was observed in some but not all clinical isolates. Increased expression of the three RNAs as determined by real-time PCR was observed in all SAG-R clinical isolates. Significant increase in cysteine and glutathione levels was observed in the resistant isolates. Our studies report the underlying mechanism of antimony resistance in the clinical isolates.
Introduction
The protozoan parasite Leishmania is the causative agent of kala-azar and is responsible for a variety of clinical manifestations. It causes a wide spectrum of diseases ranging from the simple self healing cutaneous form to the debilitating visceral form. Visceral leishmaniasis (VL) is caused by L. donovani in the Indian subcontinent. Pentavalent antimonials (SbV) are the first line of drug used in the treatment against all forms of leishmanial infections [1, 2] . Resistance to this drug is becoming a major barrier in the treatment of VL in many endemic regions particularly in India [3] . Kala-azar transmission in India is thought to be anthroponotic and postkala-azar dermal leismaniasis (PKDL) patients are considered to serve as a source for new outbreaks [4] . The post-kala-azar dermal leismaniasis (PKDL) is a sequel to VL in India and Sudan; the disease develops months to years after the patient's recovery from VL [5] . The mechanism of action of sodium antimony gluconate (SAG) remained an enigma for more than 60 years of its effective use against all forms of leishmaniasis. It is generally agreed that pentavalent form (SbV) is reduced to a more toxic trivalent form (SbIII) which constitutes the active form of the drug against the parasite [6] . Molecules possibly implicated in reduction of SbV to SbIII include host and parasite thiols and two newly discovered parasite enzymes thioldependent reductase (TDR1) and arsenate reductase (ACR2) [7] [8] [9] . A loss of drug activation is reported to lead to resistance [10] . The route of entry of SbV into Leishmania cells is still unknown but SbIII has been reported to be transported in Leishmania through aquaglyceroporin (AQP1) [11, 12] . Recent evidence has suggested that part of the mode of ©NJB, Biotechnology Society of Nepal 2 Nepjol.info/index.php/njb action of SbV could be in depleting the cells of its reduced thiols [13] . Trypanothione (TSH), a major reduced thiol of Leishmania is a N 1 , N8 bisglutathione spermidine conjugate. It is thought to bind to the active reduced form of the metal. These metal-trypanothione conjugates are either sequestered into an intracellular organelle by the ABC transporter MRPA or extruded outside the cell by an efflux pump [13] [14] [15] [16] . A number of candidate genes associated with increased thiol concentration have been described in Leishmania laboratory mutants. Resistance was induced in these mutants in vitro in the presence of antimony related metals such as arsenic or antimony [2, 17, 18] . However, till date it remains unclear as to whether similar mechanisms can be extrapolated to clinical isolates from geographical zones with a high incidence of primary antimony resistance. To address this question, we have characterized both the VL and the PKDL isolates from India and report that diverse mechanisms of resistance are operative in these isolates . This work aims at  characterizing  possible  biomarkers  for  monitoring  antimonial  resistant  visceral  leishmaniasis and post-kala-azar dermal leismaniasis in the field isolates. In the present study, we report the role of thiols and also assessed the role of ABC transporter (MRPA), ornithine decarboxylase (ODC) and γglutamylcysteine synthetase (γ-GCS) genes as potential biomarkers for monitoring antimonial resistance in Indian leishmaniasis. were designated as SAG-S (SAG-sensitive) whereas isolates from VL and PKDL patients who did not respond to SAG were designated as SAG-R (SAG-resistant). SAG-sensitive strains, AG83-S, 2001-S, MC7-S, RK1-S, MS2-S and the nine SAG-R isolates, MC4-R MC8-R, MC9-R, NR3A-R, RMP8-R, RMP19-R, RMP142-R, RMP155-R and RMP240-R have been characterized earlier [20] . Clinical history of the patient infected with the strain RK1-S showed that the interval between the cure of VL and the onset of PKDL was 2.5 years where as in the case of PKDL patients infected with the strains, MS2-S and NR3A-R, the interval between the cure of VL and the onset of PKDL was 7 and 11 years respectively. The interval between the cure of VL and the onset of PKDL for the remaining isolates is not known. The clinical isolates were maintained in vitro in the absence of the drug pressure. Promastigotes were routinely cultured at 22 0 C in modified M-199 medium (Sigma, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco/BRL, Life Technologies Scotland, UK) and 0.13 mg/mL penicillin and streptomycin. This study has the approval of the Institutional level ethics committee.
Materials and Methods

Parasite and culture conditions
DNA and RNA manipulations
Chromosomes of the clinical isolates were separated by pulse field gel electrophoresis (PFGE) in which low melting agarose blocks, containing embedded cells (10 8 /ml log phase promastigotes) were electrophoresed in a contour clamped homogeneous electric field apparatus (CHEF DRIII, Bio-Rad) as reported earlier [20] . Mid log phase promastigotes (~2 x 10 9 cells) of all the field isolates were used for isolation of genomic DNA. 5 µg of genomic DNA was digested with HindIII enzyme and subjected to electrophoresis. Total RNA was isolated from promastigotes (2 x 10 8 cells) using RNAeasy Plus Mini Kit (Qiagen). Standard protocols were followed for Southern hybridization [21] . DNA probes used in the present study included a 400-bp MRPA fragment (released from plasmid PM12 that was ©NJB, Biotechnology Society of Nepal 3 Nepjol.info/index.php/njb digested with BamHI and PstI), a 2.3-kb γGCS fragment -(derived from plasmid pspαhygroα-γGCS digested with HindIII and XbaI), a 2.0-kb ODC-full length probe (derived from plasmid pspαhygroα-ODC digested with HindIII and XbaI) and a 1.6-kb 5'-PTR1 probe derived from plasmid (psp72-Y-hygro-5'-PTR1).
cDNA synthesis and real time RT-PCR Total RNA was isolated from 10 8 Leishmania cells in the mid-log phase of growth using the RNeasy Plus Mini Kit (Qiagen) as described by the manufacturer. Quality and quantity of the RNA were determined using the RNA 6000 Nano Lab chip kit on the Bio-analyzer 2100 (Agilent Technologies). The sequences of the primers for MRPA are forward 5'-GCGCAGCCGTTTGTGCTTGTGG-3' and reverse 5'-TTGCCGTACGTCGCGATGGTGC-3' and for the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) control forward 5'-GAAGTACACGGTGGAGGCTG and reverse 5'-CGCTGATCACGACCTTCTTC primers. The sequences of the primers for ODC are forward 5'-GATGGTGCGCCCTTACTTTGC-3'and reverse 5'-TTCCATCTCCAGCGGGTTGTCC-3', and for the γGCS, forward 5'-CATTGGCTGGCGCGTTGAGTTC-3' and reverse 5'-ATGTGCGCGGCCCATATTCTCG -3' primer.
Complementary DNAs from promastigotes were synthesized from 500 ng of total RNA using the AccuSuperscript High Fidelity RT-PCR kit (Stratagene, La Jolla) and Oligo (dT) 18 primers following manufacturer's instructions. Real-time PCR was performed in triplicate in 25 l volumes using QuantiFast SYBR Green PCR Master Mix (Qiagen) in an Applied Biosystem 7500. Reactions were run using the following thermal profile: initial denaturation at 95°C for 5 min followed by 40 cycles with denaturation at 95°C for 30 s, annealing at 62°C for 1 min and extension at 72°C for 20 s. The PCR was followed by a melt curve analysis to ascertain that the expected products were amplified. The relative amount of PCR products generated from each primer set was determined based on the threshold cycle (Ct) value and amplification efficiencies and was normalized by dividing the values by the relative amount of the GAPDH gene used as a control.
Transfection and overexpression of the MRPA and γ-GCS gene
Episomal Leishmania expression vectors, pGL-NEOLUC containing luciferase encoding DNA and neomycin phosphotransferase selectable marker, psphygro-GCS containing coding sequence for heavy subunit of GCS with hygromycin phosphotransferase as selectable marker and pGEM72f-neo-MRPA containing MRPA coding DNA and neomycin phosphotransferase as selectable marker were obtained as gifts from Prof. Marc Ouellette, Centre de Recherche en Infectiologie du Centre de Recherche du CHUL, Universite Laval, Quebec, Canada. Twenty µg of each construct was transfected into L. donovani promastigotes by electroporation. Electroporation was done with a single pulse with the following parameters 450 V, 500 F (Bio-Rad). Transfectants were selected for resistance to either G418 (40 μg/ml) or hygromycin B (80 μg/ml) as described earlier [22] . After 3 h, the non-internalized parasites were washed off and SAG was added at different concentrations (10 -100 g/ml). After 5 days of drug exposure, plates containing adherent macrophages were washed and luciferase activity was determined [22] . The 50% inhibitory concentration (IC 50 ) was determined from the graph representing different concentrations of SAG plotted against relative light units (RLU) produced by luciferase expressing parasites.
Chemosensitivity profiles of SAG-S and SAG-R strains in an amastigote macrophage model
Thiol analysis
Thiols were derivatized with monobromobimane and separated by highperfomance liquid chromatography (HPLC) as reported earlier [18] .
Statistical analysis
Data was analyzed by the Student's t-test. The data is represented as mean ± S.D. The results are representative of three independent experiments. A p value of < 0.05 was considered statistically significant.
Results
Intracellular thiol levels in SAG-S and SAG-R clinical isolates
Resistance to antimonials in clinical isolates is not well defined. Understanding the mechanism of resistance to antimony in clinical isolates of L. donovani will aid in the development of biomarkers for antimony resistance and this in turn will enable the clinicians to monitor the treatment of the patients. With this background in mind, we used the previously characterized SAG-S and SAG-R, VL and PKDL clinical isolates for the present study [20] . A total of fourteen field isolates were used to assess the putative role of the ABC transporter MRPA, ornithine decarboxylase and γglutamylcysteine synthetase in antimonysusceptible and -resistant clinical isolates of L. donovani from India. As reported earlier, SAG-S isolates, AG83-S, 2001-S, MC7-S, RK1-S and MS2-S coming from SAG responsive patients had IC 50 values 6.2 ± 1.8, 0.9 ± 0.12, 8 ± 3.3, 0.01 ± 0.02 and 4.75 ± 0.12 µM respectively whereas the SAG-R isolates, MC4-R, MC8-R, MC9-R, NR3A-R, RMP8-R, RMP19-R, RMP142-R, RMP155-R, RMP240-R coming from the SAG-unresponsive patients had IC 50 s that were 2 to >10 fold higher than that of the sensitive isolate, AG83-S.(20) RK1-S was the most sensitive of all the isolates with an IC 50 of 0.01 ± 0.02 µM. Intracellular thiol levels were quantified in the SAG-S and SAG-R isolates (Figure 1 ). SAG-R isolates maintained significantly higher levels of cysteine and glutathione as compared to the SAG-S isolates. Cysteine levels in the SAG resistant strains MC4-R, MC8-R, MC9-R, NR3A-R, RMP8-R, RMP19-R, RMP142-R, RMP155-R and RMP240-R were ~1.7, ~1.6, ~1.5, ~2.7, ~2.0, ~1.8, ~1.8, ~2.0 and ~1.7 -fold higher respectively when compared to the SAG-S isolate, 2001-S (Figure 1A) . Figure 1B) . A SAG-S strain, RK1-S had glutathione levels that were ~2.1 -fold higher when compared to the SAG sensitive isolate, 2001-S. Interestingly, no significant difference was observed in the trypanothione levels between the SAG-S and SAG-R isolates ( Figure 1C) . Similar observation was made in our earlier study using a small set of clinical isolates [23] .
Gene copy number and expression profiling of the ABC transporter MRPA in SAG-S and SAG-R clinical isolates
Our earlier work on the clinical kala azar L. donovani isolates from India showed MRPA overexpression as an important SAG resistance factor [23]. To further validate, the role of MRPA gene in antimony resistance phenotype, we checked the amplification of MRPA gene by Southern blot hybridization. Southern blot hybridization of total genomic DNA digested with HindIII followed by hybridization with Nepjol.info/index.php/njb MRPA specific probe was done. SAG-sensitive and SAG-resistant field isolates showed a single hybridizing fragment of 11-kb indicating that MRPA gene exist as a single copy gene in all the isolates (Figure 2A) . Quantitation of the Southern blot hybridization signal was done using RMP240-R (Figure 2A) . No amplification was observed in the resistant isolates, NR3A-R and RMP8-R (Figure 2A) . The amplification observed in the resistant isolates was further analyzed by PFGE (Figure 2B) . None of the resistant isolates showed circular amplification as was observed in our earlier studies with limited number of isolates [23] . Interestingly, two sensitive PKDL isolates, RK1-S and MS2-S and one resistant PKDL isolate, NR3A-R had the presence of MRPA on two chromosomes as indicated by their characteristic migration in PFGE ( Figure  2B ). We had earlier reported co-amplification of pterin reductase gene (PTR1) with MRPA in the clinical isolates [23]. In the present study, coamplification of PTR1 gene with MRPA gene was not observed in any of the clinical isolates as Nepjol.info/index.php/njb determined by Southern-blot analysis using PTR1-specific probe (Figure 2A) . Figure 2C) .
Gene copy number and expression profiling of the ornithine decarboxylase (ODC) gene in SAG-S and SAG-R clinical isolates.
Ornithine decarboxylase (ODC) is the ratelimiting enzyme of the polyamine biosynthetic pathway. In addition to MRPA, overexpression of the ODC gene has been reported in the antimony resistant mutants [23-25]. These observations prompted us to determine if amplification of the ODC gene occured in our clinical isolates. Southern-blot analysis of the total genomic DNA digested with HindIII and hybridized with the ODC specific probe was done. SAG-S and SAG-R isolates showed a single copy of the ODC gene (Figure 3A) with the exception of three PKDL isolates, RK1-S, MS2-S and NR3A-R. Interestingly, two copies of the ODC gene were observed in these three PKDL isolates (Figure 3A) . (Figure 3B) . SAG-S isolate, RK1-S was an exception since it was the only sensitive isolate that showed 2.9-fold up-regulation when compared to the reference strain, 2001-S and also in comparison with all other SAG-S isolates (Figure 3B) . No uniform correlation was observed between gene amplification and ODC gene expression in these isolates.
Gene copy number and expression profiling of the γ-glutamylcysteine synthetase (γ-GCS) gene in SAG-S and SAG-R clinical isolates
In addition to MRPA and ODC, another locus that has been reported to be amplified in the antimony-resistant isolates is the GSH1 gene coding for the heavy subunit of -GCS. -GCS is the rate limiting enzyme for GSH synthesis [14, 23] . We performed Southern blot analysis of the total genomic DNA digested with HindIII and hybridized with the -GCS specific probe. Southern blot analysis of the -GCS gene showed two copies in a resistant isolate MC4-R but in all other isolates, -GCS probe hybridized to a single hybridizing fragment of 10-kb (Figure 4A) . SAG-S isolate, RK1-S was again an exception since it showed amplification of the -GCS gene ( Figure 4A) . Figure 4B ). In the present study though upregulation of -GCS was observed in all SAG-R isolates, interestingly one SAG-S isolate, RK1-S showed 5.5-fold up-regulation of GCS expression when compared to a SAG-S isolate, 2001-S (Figure 4B) . L-butathione-sulfoxamine (BSO), an inhibitor of -GCS was used to compare its effect on the SAG-S isolate, RK1-S and 2001-S. RK1-S promastigotes overexpressing -GCS were ~5 fold more resistant to BSO when compared to the IC 50 of promastigotes of the 2001-S, the IC 50 being 6.5 ± 0.5 mM and 1.3 ± 0.3 mM respectively. Nepjol.info/index.php/njb 
Comparison of GCS gene expression in SAG-S versus SAG-R field isolates was done to verify if there is any correlation between gene expression and SAG
Overexpression of MRPA or -GCS in an antimony-sensitive isolate conferred increased expression and resistance to antimony
To determine whether overexpression of MRPA and -GCS conferred antimony resistance in a sensitive isolate, we transfected MRPA or -GCS constructs into a SAG-S isolate, AG83-S. These MRPA and -GCS recombinant parasites were co-transfected with pGL-NEOLUC, encoding LUC. Intracellular amastigotes over-expressing MRPA (IC 50 , 32.3 ± 6.4 g/ml) were 3.6-fold more resistant to SAG when compared to amastigotes of the parent strain transfected with the control vector (IC 50 , 9 ± 0.5 g/ml) ( Figure  5A) . Intracellular amastigotes over-expressing -GCS were 3.3-fold resistant to SAG when compared to the sensitive L. donovani the IC 50 value being (29.7 ± 1.5 g/ml) respectively (Figure 5B) . In our previous studies we had demonstrated that the ODC overexpressors exhibited significant resistance to Pentostam compared to the wild type cells (26). Intracellular amastigotes over-expressing ODC (IC 50 , > 80 g/ml) were >8.8-fold more resistant to SAG when compared to amastigotes of the parent strain transfected with the control vector [26].
Discussion
Currently, chemotherapy is the only effective way to control Leishmania infection. Pentavalent antimonials are the mainstay of therapy in the treatment of visceral leishmaniasis [27] . Increase in resistance to SAG has led to an upsurge in therapeutic failure and in the absence of limited chemotherapeutic alternatives, it is extremely necessary to identify biomarkers for monitoring antimony resistance. Trivalent form of the antimonial drug (SbIII) is the prodrug that is formed by conversion of pentavalent antimony (SbV) by a putative metalloid reductase present in the macrophages [28] . Antimonial resistance in both laboratory mutants and clinical isolates has been associated with (a) decreased uptake of the drug through aquaglyceroporin (AQP1) that codes for the protein responsible for SbIII transport Nepjol.info/index.php/njb [11, 12, 20 ,29] (b) Over expression of ODC and γ-GCS enzymes of the trypanothione biosynthetic pathway [2, 25] and (c) increased expression of the ABC transporter MRPA, which sequesters SbIII-thiol conjugate [16, 23] . We had earlier reported decreased uptake of antimony in all nine SAG-R isolates used in the present study. Down-regulation of SbIII influx pump; aquaglyceroporin (AQP1) was observed in seven out of the nine resistant isolates Strains, MC8-R and NR3A-R were an exception since they showed up-regulation of AQP1 gene expression [20] . The ABC transporter gene MRPA causes drug sequestration in Leishmania promastigotes and amastigotes selected for SbIII resistance [17, 30] . Increased copy number of MRPA has been reported in SbIII resistant mutant [2] . Our earlier studies using limited number of SAG-S and SAG-R clinical isolates showed amplification of MRPA gene as part of an extrachromosomal circle [23] . In the present study, we found distinct correlation between copy number of MRPA gene and antimony sensitivity in a majority of the isolates (Figure 2A ). However, two SAG-R strains, NR3A-R and RMP8-R were an exception. We have reported earlier that ABC transporter gene MRPA was amplified in three out of four resistant VL isolates as part of the extrachromosmal circle and coamplifcation of PTR1 along with MRPA suggested amplification of the H locus in SAG-resistant clinical isolates [23] . In the present study, co-amplification of PTR1 gene with MRPA gene was not observed in any of the clinical isolates. CHEF gel analysis of the SAG-S and SAG-R isolates did not show any circular amplification in any of the SAG-R isolates. MRPA gene expression in SAG-S versus SAG-R field isolates showed correlation between MRPA gene expression and SAG susceptibility profile of the clinical isolates. The present observation validated our earlier results where we have shown correlation between MRPA gene expressions with the antimony resistant clinical profile in the field conditions [23].
In our previous study amplification of ODC gene was noted in the resistant isolates but not that of the γ-GCS [23] . In another study on L. donovani isolates from Nepal, expression of γ-GCS and ODC was significantly decreased in the resistant isolates [31] . In the present study we observed increased expression of ODC gene and γ-GCS in all SAG-R isolates. It has been reported earlier that ABC transporter MRPA, confers resistance to antimonials by sequestration of metal thiol conjugates in an intracellular organelle located close to the flagellar pocket [16] . This model has been demonstrated in promastigotes of L. tarentolae, in amastigotes and also in clinical isolates from India [16, 23, 30] . These observations clearly highlighted the importance of intracellular thiol in MRPA mediated efflux of the antimony. An increase in cysteine and glutathione levels were reported in antimony resistant L. donovani clinical isolates [23] . In the present study also, we observed increase in cysteine and glutathione levels in all SAG-R isolates. However, no change in trypanothione levels were observed in SAG-R isolates in comparison to SAG-S isolates. Similar observation was made in our analysis of the mode of action of antimony in clinical isolates and earlier studies in L. infantum resistant to Sb(III) [23] . It was pointed out that antimony possibly depleted trypanothione by efflux of Sbtrypanothione conjugate [16] . It is possible that the efflux system is increased in the resistant isolates thereby leading to increased trypanothione efflux. This would explain the constant levels of trypanothione in the present study in the resistant isolates. RK1-S though a SAG-S isolate, was an exception to the mutlifactorial antimony resistant mechanisms reported in clinical isolates and also in the lab based resistant isolates. Clinical history of the RK1-S patient showed that the interval between the cure of VL and the onset of PKDL was 2.5 years where as MS2-S and NR3A-R, PKDL isolates the interval between the cure of VL and the onset of PKDL was 7 and 11 years respectively. It will be interesting to look at the PKDL isolates with known clinical history in order to determine if this interval has a role to play in antimony susceptibility/resistance. The data presented here in VL and for the first time in PKDL isolates, establishes the relevance of overexpression of γ-GCS and ODC and an increased expression of MRPA that may be responsible for an increased efflux of thiol-Sb-III conjugate. Our data further confirms that resistance mechanisms present in the laboratory strains can be found in the clinical isolates. Further work is presently going on the laboratory to get a global overview of the resistant mechanism by proteomics approach in order to find other possible resistant determinants. It will further help in proper selection of therapeutic regimen and improve treatment strategy against leishmaniasis.
